Similarly, elevated coexpression of PIK3CA with additional pluripotency markers, such as SOX2 (Supplementary Fig. S3A), PROM1 (Supplementary Fig. S3B), NANOG (Supplementary Fig. S3C), or CD44 (Supplementary Fig. S3D) exhibited an enhanced trend for poor prognosis in the PN subtype, and this trend was significant when PIK3CA was coexpressed with PROM1 (P = 0.2; Supplementary Fig. S3B) or CD44 (P = 0.04; Supplementary Fig. S3D). This evidence concerns the gene NANOG and poikiloderma with neutropenia.